Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • HS-110
    • HS-130
    • Expanded Access
    • Scientific Publications
  • Investors
  • News & Media
  • Careers
  • Contact

News Releases

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Aug 26, 2021

Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board

Aug 23, 2021

Heat Biologics Announces New Additions to Biothreat Advisory Board

Aug 19, 2021

Heat Biologics Announces Formation of Biothreat Advisory Board

Aug 18, 2021

Heat Biologics Provides Second Quarter 2021 Business Update

Aug 11, 2021

Heat Biologics Announces Groundbreaking for New San Antonio Facility

Aug 9, 2021

Heat Biologics Joins Russell Microcap® Index

Jun 28, 2021

Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters

Jun 23, 2021

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

Jun 4, 2021

Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

May 20, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...29
    NightHawk Biosciences

    OUR ECOSYSTEM

    SkunkWorx Bio
    Heat Biologics
    Elusys Therapeutics Inc.
    Pelican Therapeutics
    Scorpion Biological Services
    © 2022 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn